Special Issue

Novel Antibiotics from Actinomycetes

Message from the Guest Editor

Antimicrobial resistance has become one of the major threats to public health. In 2017, the WHO published a list of priority pathogens for which new antibiotics are urgently needed. Actinomycetes are well-known producers of antibiotics and the origin of most anti-infective drugs in use today. Thanks to the advent and continuing improvement of breakthrough technologies, these bacteria will also be one of the most important sources for novel antibiotics in the decades to come. This Special Issue aims to provide a forum to disseminate the latest results on novel antibiotics from actinomycetes. Papers on the identification and characterization of novel antimicrobials from actinomycetes, new derivatives of natural compounds, strategies to overcome antibiotic resistances, and new techniques and strategies to identify antibiotics are welcome. We kindly invite primary research articles as well as reviews of the state of the art. All articles will be peer-reviewed to ensure that high-quality contributions are included in this issue. Keywords: antibiotics; actinomycetes; drug discovery; natural products; biosynthesis

Guest Editor

Prof. Dr. Yvonne Mast

Department of Bioresources for Bioeconomy and Health Research, Leibniz Institute DSMZ-German Culture Collection for Microorganisms and Cell Cultures, 38124 Braunschweig, Germany

Deadline for manuscript submissions

closed (31 October 2020)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed

mdpi.com/si/30516

Antibiotics
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI